GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » EV-to-EBIT

Burzynski Research Institute (Burzynski Research Institute) EV-to-EBIT : -4.34 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Burzynski Research Institute's Enterprise Value is $5.15 Mil. Burzynski Research Institute's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 was $-1.19 Mil. Therefore, Burzynski Research Institute's EV-to-EBIT for today is -4.34.

The historical rank and industry rank for Burzynski Research Institute's EV-to-EBIT or its related term are showing as below:

BZYR' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.6   Med: 0   Max: 1.29
Current: -4.34

During the past 13 years, the highest EV-to-EBIT of Burzynski Research Institute was 1.29. The lowest was -19.60. And the median was 0.00.

BZYR's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs BZYR: -4.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Burzynski Research Institute's Enterprise Value for the quarter that ended in Nov. 2023 was $5.53 Mil. Burzynski Research Institute's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 was $-1.19 Mil. Burzynski Research Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2023 was -21.47%.


Burzynski Research Institute EV-to-EBIT Historical Data

The historical data trend for Burzynski Research Institute's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute EV-to-EBIT Chart

Burzynski Research Institute Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.60 -0.80 -2.93 -4.03 -5.27

Burzynski Research Institute Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.49 -5.27 -8.14 -6.30 -4.66

Competitive Comparison of Burzynski Research Institute's EV-to-EBIT

For the Biotechnology subindustry, Burzynski Research Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's EV-to-EBIT falls into.



Burzynski Research Institute EV-to-EBIT Calculation

Burzynski Research Institute's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.151/-1.188
=-4.34

Burzynski Research Institute's current Enterprise Value is $5.15 Mil.
Burzynski Research Institute's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute  (OTCPK:BZYR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Burzynski Research Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Nov. 2023 ) =EBIT / Enterprise Value (Q: Nov. 2023 )
=-1.188/5.5329608
=-21.47 %

Burzynski Research Institute's Enterprise Value for the quarter that ended in Nov. 2023 was $5.53 Mil.
Burzynski Research Institute's EBIT for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute (Burzynski Research Institute) Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines